We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Mast Group Appointed European Distributor of Kanto Tests

By Labmedica staff writers
Posted on 14 Nov 2006
The Kanto Chemical Company (Tokyo, Japan) has appointed Mast Group Ltd. More...
(Merseyside, UK) as its authorized representative and exclusive European distributor for a range of tests for extended-spectrum beta-lactamase (ESbL) detection.

The Cica Beta products of Kanto incorporate the use of a novel chromogenic compound to differentiate between the various beta lactamase enzymes and permit confirmation of an organism as an ESbL, metallo-beta lactamase (MBL), or AmpC-type lactamase producer. Separate kits are available for each type of beta lactamase enzyme and each kit is color coded for simple identification. The kits can be used individually or in combination for comprehensive enzyme profiling.

Lactamase-producing strains of bacteria are more resistant to antibiotics and cause infections that are difficult to treat. In many instances, only two oral antibiotics and a very limited group of intravenous antibiotics are effective.

Suspect bacterial colonies are streaked onto each strip and identification is made by a clear color change from yellow to red. Results are available within 15 minutes, permitting rapid and accurate identification. The Cica Beta tests supplement the existing range of Mast's identification and antibiotic sensitivity products.

The Cica Beta kits rapidly detect enzyme production in Gram-negative isolates from patients with severe infection. ESbL production by a total of 304 strains of Klebsiella spp., Escherichia coli, and Proteus mirabilis was tested by a Cica Beta kit as well as the phenotypic confirmatory disk test (using cefotaxime and ceftazidime, with and without clavulanate). The kit showed 95.5% and 98.1% sensitivity and specificity, respectively, as compared to the disk test, and thus proved to be an appropriate tool for the rapid detection of ESbL.



Related Links:
Kanto Chemical
Mast Group

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.